Langren Carl W. 4

Accession 0001126234-19-000103

CIK 0001126234other

View on SEC.gov Company Profile

Filed

Aug 1, 8:00 PM ET

Accepted

Aug 2, 6:38 PM ET

Size

38.7 KB

Accession

0001126234-19-000103

Insider Transaction Report

Form 4

Period: 2019-07-31

NEWLINK GENETICS CORP(NLNK)

Langren Carl W.

Principal Accounting Officer

Transactions

Award
Stock Option (Right to Buy)
2019-07-31+11,719→ 11,719 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (11,719 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+2,211→ 2,211 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (2,211 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−55,000→ 0 total
Exercise: $7.85→ Common Stock (55,000 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+3,438→ 3,438 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (3,438 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+24,250→ 24,250 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (24,250 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+4,821→ 4,821 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (4,821 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+2,293→ 2,293 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (2,293 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+2,291→ 2,291 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (2,291 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+2,291→ 2,291 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (2,291 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+11,458→ 11,458 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (11,458 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−37,500→ 0 total
Exercise: $10.55Exp: 2027-01-02→ Common Stock (37,500 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+4,870→ 4,870 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (4,870 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+4,297→ 4,297 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (4,297 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+4,583→ 4,583 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (4,583 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+3,438→ 3,438 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (3,438 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−100,000→ 0 total
Exercise: $3.17Exp: 2028-07-31→ Common Stock (100,000 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+14,293→ 14,293 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (14,293 underlying)

Footnotes (6)

[F1]The option provided that it would vest in 48 equal monthly installments beginning the first month after grant date subject to the Reporting Person's continuous service as of such date.
[F2]On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.
[F3]The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date.
[F4]The option vests as to 50% on the second anniversary of grant date and the remaining 50% on the third anniversary of grant date.
[F5]The option provided that 50% of the option grant would vest in a series of 48 successive equal monthly installments beginning on April 9, 2018 and the remaining 50% would vest upon specified performance objectives, in each case, provided that as the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
[F6]Unless otherwise disclosed, the option expires ten years after the date of grant.

Documents

1 file

4
wf-form4_156478551914901.xmlPrimary
FORM 4

Issuer

NEWLINK GENETICS CORP

CIK 0001126234

→

Entity typeother

Related Parties

filerCIK 0001591245

Filing Metadata

Form type: 4
Filed: Aug 1, 8:00 PM ET
Accepted: Aug 2, 6:38 PM ET
Size: 38.7 KB

View on SEC.gov